Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Osteoporosis drug may strengthen bones beyond density, new study hints

NCT ID NCT01155245

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how teriparatide, a bone-building drug for severe osteoporosis, affects bone structure in postmenopausal women. Researchers will use a special scanner to see changes in bone thickness and tiny connecting rods at the wrist and ankle over 24 months. The goal is to understand if the drug improves bone quality beyond just mineral density, which could help predict fracture risk better. Sixty women with a history of fractures or very low bone density are enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Teriparatide (Forteo pen)
What this could lead to
If successful, this could show that teriparatide improves bone structure at the wrist and ankle, helping doctors better predict fracture risk and tailor osteoporosis treatment.
What could go wrong
This is a small, early-stage study with only 60 participants, and it focuses on bone structure changes rather than directly measuring fracture reduction. Results may not apply to all women with osteoporosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jun 2008

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

community dwelling postmenopausal women with osteoporosis and women with atypical femur fractures

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of fragility fracture OR * High risk for fractures OR * Very low BMD (T-score ≤ -2.5) OR * Failed or intolerant to bisphosphonates * Baseline serum levels of calcium, urate, ALP, PTH, creatinine and 25-hydroxyvitamin D \[25(OH)D\] must be within acceptable normal limits Exclusion Criteria: * History of skeletal irradiation * Those at increased risk for osteosarcoma * Diagnosis of Paget's disease * History of primary hyperparathyroidism * Significant renal impairment * Vitamin D deficiency * On steroids or have other causes of secondary osteoporosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoporosis

Contacts and locations

Locations

  • University Health Network, TGH

    Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.